Clearside Biomedical Investor Relations Material

Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the development of therapies for the treatment of eye diseases. The company focuses on treating conditions affecting the retina and choroid through its proprietary SCS Microinjector platform, which delivers drugs directly to the back of the eye. Clearside's approach aims to enhance the efficacy of treatments for serious vision-threatening diseases, including macular edema and uveitis. The company is headquartered in Alpharetta, United States, and its shares are listed on the NASDAQ.